HIF, Hypoxia Research & Stem Cell News

Entest BioMedical Files Patent Application for Selective Targeting of Stem Cells to Lung Using Photoceutical Devices

New Technology to Increase Efficacy of Adult Stem Cells in COPD Treatment

Entest BioMedical announced today it has filed a second patent application in the area of Chronic Obstructive Pulmonary Disease (COPD). This new patent application builds upon the Company’s previously filed COPD patent application and involves the use of photoceutical devices to target stem cells toward areas impacted by COPD in the lungs.

Steve Josephs, PhD, a Scientific Advisor to the Company stated “that by using photoceutical devices in treating COPD, it is believed stem cells can be focused on areas of the lungs where there is damage. Furthermore, being able to target specific areas and draw stem cells to those areas should produce greater efficacy in patient treatment outcomes. ”

David Koos, Chairman and CEO of Entest stated, “This new patent application we filed covers methods of enhancing our previously disclosed adult stem cell technologies in the treatment of COPD. It is our belief the use of photoceuticals devices coupled with adult stem cell therapy is a treatment model completely new and unique to addressing this terrible disease.”

Entest’s treatment approach for COPD is based on the development of easy-toimplement therapies involving the use of stem cells, and other cells found in the fat tissue of the patient. By incorporating photoceutical devices currently in use for other clinical treatments, this invention discloses methods of increasing the rate of cell homing, retention, and growth factor production in the lung.

from http://www.entestbio.com/latest-news/entest-biomedical-files-patent-application-for-selective-targeting-of-stem-cells-to-lung-using-photoceutical-devices.html

Related posts:

• EU Denies Stem Cell Patent: “They destroy embryos”
  According to the European Patent Office, there will be no patents in Europe for embryonic stem cells. The board decided to fully uphold a sentence from June by a
• ‘Adipose-derived’ Stem Cells Could Help Traumatic Brain Injury Patients
  Image by cloois via Flickr

  Dr. Feng Lin, Director of Research at Bio-Matrix Scientific Group Inc. (OTCBulletinBoard: BMSN) and Entest BioMedical Inc., today stated that he believes that an effective new

• Cell Targeting hopes to take purpose to stem cell therapy
  Joseph Wagner sees most cell-therapy companies offering little more than a bag of cells.
  His company will give the bag a little direction.

  Cell Targeting is developing technology that can point stem

• Novocell announces patent on insulin-producing stem-cell technique
  Image via Wikipedia

  SAN DIEGO – Novocell, a small, privately held San Diego company, may have found new ways to make money from its technique for coaxing human embryonic stem cells

• MultiCell teams with Maxim Biotech to study live stem cells and cancer
  Rhode Island-based biotechnology company MultiCell Technologies Inc. is teaming up with Maxim Biotech Inc. under cooperative research and development agreement to develop products for studying liver stem cells and liver

If you need more information about STEM CELLS please visit Latest Stem Cells News

This post comes from Latest Stem Cells News
(Digital Fingerprint: 0f6d53ed7d5f01118cf01c21fc9b9d58)